CPHI Webinar: Early multi-functional approach is the best way to incorporate patient centricity into drug formulations
The concept of patient centricity has many nuances, and designing dosage forms needs to be underpinned by a multi-functional perspective utilised as early as possible, say experts
Designing effective patient-centric dosage forms needs to be underpinned by a practical multi-functional view which considers all the angles, according to a panel of experts speaking at a recent CPHI Webinar, available here on-demand.
In the Webinar Defining and Designing Patient-Centric Dosage Forms sponsored by SPI Pharma and chaired by Leanne West, Principal Research Scientist & Chief Engineer of Paediatric Technologies, Georgia Tech, the implications of designing drugs that tick all the boxes for patient centricity were discussed both from a commercial and academic perspective.
Dr Graeme Macleod, Global Research & Development Manager, SPI Pharma said it was important to take a multi-functional view on what is meant by patient centricity: “What does your target patient group look like, what is the disease, is the disease chronic or acute, where is the patient actually receiving the medicine, and are they in a particular group where it’s difficult to take the medication?”
He added that from a pharmaceutical development point of view, it was essential to get as much information as early in the development process as possible and not lose sight of certain commercial considerations such as ascertaining what technologies are available inhouse and the cost of development.
“From a formulation perspective, you’ve really got to think about not only designing the right dosage form, but also about what you can achieve practically,” he said. “In general, it’s about having a dose form that is safe and efficacious and trying to make it designed to be as patient centric as possible within the certain limitations we have.”
Nielsen Hobbs, Executive Editor, Policy and Regulation, Pink Sheet said the more formulation developers hold discussions with patients and take a “blue sky approach” to what is possible, “the easier their development could end up being.”
Hannah Batchelor, Professor, Strathclyde Institute of Pharmacy and Biomedical Sciences said patient centricity should be considered as early as possible in the drug development process.
She gave the example of a project for an oral product for rheumatoid arthritis in which developers did look from the very beginning at issues such as the size and shape of the tablet for easier handling and grip as patients may have dexterity issues.
“It is looked at relatively early; in development pipeline terms, it’s probably just prior to Phase I is where I’ve seen patient centricity considered previously,” she added.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance